Hussman Strategic Advisors Inc. Takes $36,000 Position in Q32 Bio Inc. (NASDAQ:QTTB)

Hussman Strategic Advisors Inc. acquired a new stake in Q32 Bio Inc. (NASDAQ:QTTB) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 10,500 shares of the company’s stock, valued at approximately $36,000.

Other hedge funds also recently made changes to their positions in the company. Values First Advisors Inc. acquired a new stake in shares of Q32 Bio in the third quarter valued at approximately $33,000. BNP Paribas Financial Markets increased its stake in shares of Q32 Bio by 199.1% during the third quarter. BNP Paribas Financial Markets now owns 1,298 shares of the company’s stock worth $58,000 after purchasing an additional 864 shares during the period. MetLife Investment Management LLC bought a new position in shares of Q32 Bio during the third quarter worth approximately $159,000. Franklin Resources Inc. bought a new position in shares of Q32 Bio during the third quarter worth approximately $225,000. Finally, Barclays PLC increased its stake in shares of Q32 Bio by 105.2% during the third quarter. Barclays PLC now owns 10,443 shares of the company’s stock worth $465,000 after purchasing an additional 5,353 shares during the period. 31.32% of the stock is owned by institutional investors and hedge funds.

Q32 Bio Trading Up 0.4 %

Shares of QTTB opened at $2.43 on Friday. Q32 Bio Inc. has a 52-week low of $2.35 and a 52-week high of $53.79. The business’s fifty day moving average is $3.22 and its 200-day moving average is $26.97. The company has a debt-to-equity ratio of 0.61, a quick ratio of 6.53 and a current ratio of 6.53. The firm has a market cap of $29.60 million, a price-to-earnings ratio of -0.17 and a beta of -0.32.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Raymond James reiterated an “outperform” rating and set a $22.00 target price (down previously from $90.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Leerink Partners reiterated a “market perform” rating and set a $9.00 target price (down previously from $68.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Leerink Partnrs lowered Q32 Bio from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Oppenheimer lowered their price objective on Q32 Bio from $80.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Finally, Guggenheim lowered Q32 Bio from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 11th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $24.86.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.